Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | TNF | P01375 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.46 |
| ▸ | CLK1 | P49759 | 2/20 | 0.46 |
| ▸ | CLK2 | P49760 | 2/20 | 0.46 |
| ▸ | CLK3 | P49761 | 2/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30369965 | 0.85 | HTT (0.55) | HTTNCOA3TNFCA1CA2 | |
| SCHEMBL1202005 | 0.85 | HTT (1.00) | HTTNCOA3TNFCA1CA2 | |
| SCHEMBL28304074 | 0.83 | HTT (0.96) | HTTNCOA3TNFCA1CA2 | |
| SCHEMBL31227884 | 0.81 | HTT (0.59) | HTTNCOA3TNFCA1CA2 | |
| SCHEMBL2006516 | 0.81 | TNF (0.49) | HTTNCOA3TNFCA1CA2 | |
| SCHEMBL30183020 | 0.78 | HTT (0.59) | HTTNCOA3TNFCDK5DYRK1A | |
| Hydrochloric Acid SCHEMBL31354899 | 0.77 | HTT (0.58) | HTTNCOA3TNFCDK5DYRK1A | |
| SCHEMBL30210936 | 0.76 | NCOA3 (0.51) | HTTNCOA3TNFCDK5DYRK1A | |
| SCHEMBL59702 | 0.74 | CA1 (0.69) | HTTCA1CA2DYRK1ACLK1 | |
| SCHEMBL10399061 | 0.74 | MELK (0.49) | HTTNCOA3TNFALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120028308-A | Small molecule Raman probe, bar code probe, encoding method and application thereof | 北京大学 | 2025-05-23 | — | — | CN | claimed |
| WO-2025080592-A1 | COMBINATION COMPRISING A KRAS G12D INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025080593-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR AND PD-1 INHIBITOR OR PD-L1 INHIBITOR | INCYTE CORPORATION (US) | 2025-04-17 | — | — | WO | claimed |
| CN-118632696-A | Combination therapy comprising FGFR inhibitor and KRAS inhibitor | 因赛特公司 | 2024-09-10 | — | — | CN | claimed |
| EP-4415824-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-08-21 | — | — | EP | claimed |
| CN-118525017-A | Quinoline compounds as KRAS inhibitors | 因赛特公司 | 2024-08-20 | — | — | CN | claimed |
| US-20230226040-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | INCYTE CORPORATION | 2023-07-20 | — | — | US | claimed |
| WO-2023064857-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-04-20 | — | — | WO | claimed |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| CN-120028308-A | Small molecule Raman probe, bar code probe, encoding method and application thereof | 北京大学 | 2025-05-23 | — | — | CN | disclosed |
| WO-2025080593-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR AND PD-1 INHIBITOR OR PD-L1 INHIBITOR | INCYTE CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025080592-A1 | COMBINATION COMPRISING A KRAS G12D INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| CN-1871008-A | Triazolo-pyridazine compounds and derivatives thereof useful in the treatment of neuropathic pain | MERCK & CO INC (US) | 2006-11-29 | — | — | CN | disclosed |
| WO-2005040137-A1 | AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-6534510-B2 | Anticoagulants | MERCK & CO., INC. | 2003-03-18 | — | — | US | disclosed |
| EP-1267876-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020006923-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001070229-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | HTT 2237/4885NCOA3 860/4885TNF 4685/4885 |
| US-20020006923-A1 | Thrombin inhibitors | F2, F11, F12 | HTT 473/4885NCOA3 3569/4885TNF 1945/4885 |
| US-20230226040-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | KRAS, FGFR2, FGFR3 | HTT 3974/4885NCOA3 480/4885TNF 4699/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | HTT 2237/4885NCOA3 860/4885TNF 4685/4885 |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | HTT 2553/4885NCOA3 1080/4885TNF 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.